Sanofi’s Commitment to Hematology

Originally published on Sanofi.com.

Blood cancers and rare blood disorders account for some of the most challenging diseases to treat, and patients often have limited therapeutic options available to them. Sanofi is committed to significantly improving the health and lives of people with a range of hematologic conditions.

Across these therapeutic areas, Sanofi is focused on a number of diseases where patients need new treatment options, including hemophilia, cold agglutinin disease, acquired thrombotic thrombocytopenic purpura and multiple myeloma.

Sanofi’s Commitment to Hematology
Bill Sibold, Executive Vice President and Head of Sanofi Genzyme, and John Reed, Global Head of Research and Development, share their insights on how Sanofi is drawing on its deep expertise in hematology and robust R&D programs to address numerous hematologic conditions.

Related

Trending Now

Follow us

Most Popular

Join Our Newsletter

Get the top workplace fairness news delivered straight to your inbox